News
   Date
              Subject
 2018-05- Taiwan FDA Approves Phase I Clinical Trial of NEGF (BB-101) for the
  Treatment of Diabetic Foot Ulcers.
 2018-05-23 Patent application of “A composition for wound healing and use thereof”
  was granted by European Patent Office.
 2018-04-11 Awarded grant funding of $15M NTD for “Phase I Clinical Study Program
  for Wound Therapy Protein Drug BB-101” from Department of Industrial
  Technology of MOEA.
 2015-11-24 US FDA Approves Phase I Clinical Trial of NEGF (BB-101) for the
  Treatment of Diabetic Foot Ulcers.
  From drug discovery to clinical trial, all the development works of BB-101
  Blue Blood. FDA’s approval for clinical trial is an important milestone not only for Blue
  is executed by Blue Blood. FDA’s approval for clinical trial is an important
  milestone not only for Blue Blood, but also for Taiwan Biotechnology
  Industry.

 

--------------------------------------------

   
 2013-06-21 Patent application of “A composition for wound healing and use thereof”
  was granted by Taiwan Intellectual Property Office.
 2013-06-11 Patent application of “Methods and compositions for bactericide,
  bacteriostatic and anti-inflammation” was granted by Japan Patent Office.
 2013-05-28 Patent application of “Methods and compositions for bactericide,
  bacteriostatic and anti-inflammation” was granted by Korean Intellectual
  Property Office.
 2013-05-20 The ongoing NEGF protein preclinical study was successfully awarded the
  Industrial R&D Promotional Loans of 27M NTD from Industrial
  Development Bureau, Ministry of Economic Affairs.
 2013-03-05 In collaboration with Charles River Laboratories, U.S.A, BlueBlood
  effectively conducted the 28-day repeat dose dermal toxicity study in
  mini-pigs.
 2013-02-05 BlueBlood has partnered with Dow Pharmaceuticals Sciences (U.S.A) on
  GMP manufacturing of Phase I clinical supplies

 

--------------------------------------------

   
 2012-10-23 Patent application of “Method for treating wounds using an EGF-like
  domain of Thrombomodulin” was granted by United States Patent and
  Trademark Office.
 2012-10-23 Patent application of “Methods and compositions for treating ischemia” was
  granted by United States Patent and Trademark Office.
 2012-09-17 Awarded grant funding of $15M NTD for “Preclinical Study Program for
  Wound Therapy Protein Drug BB-101” from Department of Industrial
  Technology of MOEA.
 2012-07-16 Engaged Associate Professor Chuan-Liang Kao as technical consultant in
  developing Neutralization assay and antibody screening diagnostic kit for
  Cytomegalovirus.
 2012-06-12 Conducted a GLP-compliance study: “A 28-day Study of NEGF by
  Subcutaneous Injection in Rats with a 16-day Recovery Period” at Charles
  River Laboratories Inc.
 2012-06-11 Patent application of “Methods and compositions for bactericide,
  bacteriostatic and anti-inflammation” was granted by Taiwan Intellectual
  Property Office.
 2012-04-01 Patent application of “Methods and compositions for bactericide,
  bacteriostatic and anti-inflammation” was granted by European Patent
  Office.

 

-------------------------------------------

   
 2011-11-30 Patent application of “Methods and compositions for bactericide,
  bacteriostatic and anti-inflammation” was granted by Intellectual Property
  Office of Singapore.
 2011-11-16 Attend pre-IND meeting with US FDA for topical recombinant NEGF
  (BB-101).
 2011-09-06 Patent application of “A composition for wound healing and use thereof”
  was granted by Japan Patent Office.
 2011-05-10 Patent application of “Dextromethorphan-Based Method for Treating Acne”
  was granted by United States Patent and Trademark Office.
 2011-04-28 Patent application of “A composition for wound healing and use thereof”
  was granted by Korean Intellectual Property Office.
 2011-04-05 Patent application of “Methods and compositions for bactericide,
  bacteriostatic and anti-inflammation” was granted by IP Australia.